Teladoc Stock Surges as Deutsche Bank Calls Shares "Compelling" and Sees Exit Upside
Deutsche Bank upgrades Teladoc Health to Buy from Hold with $11 price target, calling valuation compelling amid BetterHelp stabilization and potential exit upside.
Already have an account? Sign in.